
Viveve
Viveve Medical | Improving Vaginal Laxity | Home.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | $32.4m | Post IPO Equity | |
Total Funding | 000k |








USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | - | - | (17 %) | 17 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | - | - | (440 %) | (343 %) | (321 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | - | (648 %) | (400 %) | (343 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | - | - | 131 % | 94 % | 150 % |
Source: Company filings or news article
Related Content
Viveve is a health and wellness company specializing in nonsurgical radiofrequency treatments designed to rebuild tissue and enhance collagen production. The company's core product, the Viveve Treatment, utilizes a small probe that emits cryogen cooling to protect tissue while radiofrequency waves heat the tissue, prompting new collagen production. This treatment is typically completed in a single 30-45 minute session and is marketed as safe, comfortable, and clinically proven. Viveve serves a diverse client base, including women seeking solutions for vaginal laxity, sexual function, and urinary incontinence. The company operates in the global healthcare market, with its treatments available in over 50 countries. Viveve's business model involves partnering with healthcare providers and distributors to offer its solutions, generating revenue through the sale of its treatment systems and related products. The company also offers InControl products aimed at strengthening pelvic muscles, which are part of the core muscle group and require regular exercise, especially after childbirth.
Keywords: radiofrequency treatment, collagen production, vaginal laxity, sexual function, urinary incontinence, nonsurgical, healthcare providers, pelvic muscles, cryogen cooling, global market.